首页> 外文期刊>Vaccine >HSP70 gene fused with Hantavirus S segment DNA significantly enhances the DNA vaccine potency against hantaviral nucleocapsid protein in vivo
【24h】

HSP70 gene fused with Hantavirus S segment DNA significantly enhances the DNA vaccine potency against hantaviral nucleocapsid protein in vivo

机译:与汉坦病毒S区段DNA融合的HSP70基因在体内显着增强了针对汉坦病毒核衣壳蛋白的DNA疫苗效力

获取原文
获取原文并翻译 | 示例
           

摘要

Heat shock proteins (HSPs) have been shown to act as adjuvants when coadministered with peptide antigens or given as fusion proteins and enhance the vaccination efficiency. To evaluate the enhancement of the potency of Hantaan virus (HTNV) nucleocapsid protein (NP) immunogenicity by heat shock protein 70 (HSP70), we developed a novel chimeric HTNV S-HSP70 DNA vaccine plasmid by genetically linking HSP70 gene to the full-length HTNV S segment DNA (HTNV S DNA). C57BL/6 mice were immunized with this plasmid followed by a subsequent boost with homologous recombinant protein. The levels of HTNV NP-specific antibody and cellular immune response were measured by use of ELISA, fluorescence activated cell sorter (FACS) analysis, cytotoxicity assay, and IFN-gamma ELISPOT assay. We found that HTNV S-HSP70 DNA vaccination significantly increased the levels of HTNV NP-specific antibody, IgG2a/IgG1 ratio, IFN-gamma producing CD8+ T-cell precursor frequencies, and cytotoxic T lymphocyte (CTL) response when compared with immunization with HTNV S DNA alone or HTNV S DNA physically mixed with HSP70 DNA. By contrast, HSP70 DNA or vector DNA immunization could not induce appreciable levels of specific antibodies and CTL response. Thus, we demonstrate for the first time that HSP70-based HTNV S DNA can induce both humoral and cellular immune response specific for HTNV NP and is a promising candidate DNA vaccine for HTNV infection.
机译:当与肽抗原共同施用或作为融合蛋白给予时,热休克蛋白(HSP)已显示出可作为佐剂并提高疫苗接种效率。为了评估热休克蛋白70(HSP70)对汉坦病毒(HTNV)核衣壳蛋白(NP)免疫原性的增强作用,我们通过将HSP70基因与全长遗传连接,开发了新型嵌合HTNV S-HSP70 DNA疫苗质粒。 HTNV S片段DNA(HTNV S DNA)。用该质粒免疫C57BL / 6小鼠,随后用同源重组蛋白加强免疫。通过使用ELISA,荧光激活细胞分选仪(FACS)分析,细胞毒性测定和IFN-γELISPOT测定来测量HTNV NP特异性抗体和细胞免疫应答的水平。我们发现与HTNV免疫相比,HTNV S-HSP70 DNA疫苗接种显着提高了HTNV NP特异性抗体的水平,IgG2a / IgG1比,产生IFN-γ的CD8 + T细胞前体频率以及细胞毒性T淋巴细胞(CTL)反应。单独的S DNA或与HSP70 DNA物理混合的HTNV S DNA。相比之下,HSP70 DNA或载体DNA免疫不能诱导明显水平的特异性抗体和CTL反应。因此,我们首次证明了基于HSP70的HTNV S DNA可以诱导HTNV NP特异的体液和细胞免疫应答,并且是HTNV感染的有希望的候选DNA疫苗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号